Anavex Life Sciences has announced encouraging results from a recent phase 2b/3 trial of its investigational
therapy, blarcamesine (ANAVEX2-73), aimed at treating early Alzheimer disease.
The study, conducted across multiple countries, involved 508 participants and
demonstrated a significant reduction in pathological amyloid-ß levels, a
hallmark of Alzheimer’s pathology.
The trial, which included randomized, double-blind, placebo-controlled parameters, saw 338
patients receiving blarcamesine and 170 on a placebo for 48 weeks. Remarkably,
the study revealed a pronounced decrease in brain volume loss among those
treated with blarcamesine, as evidenced by MRI scans. This finding suggests a
potential breakthrough in Alzheimer’s treatment, targeting both cognitive
decline and neurodegeneration.
Blarcamesine, developed by Anavex, is distinguished by its oral administration
and favorable safety profile. The therapy showed a statistically significant
improvement in the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog)
scores, indicating its efficacy in enhancing cognitive functions. Furthermore,
the study observed improvements in the Clinical Dementia Rating Scale,
reinforcing the potential of blarcamesine to slow disease progression.
Common adverse effects, such as dizziness, were reported predominantly during the titration
phase but were generally mild to moderate in severity. This safety insight is
crucial as it emphasizes the therapy’s tolerability among patients.
Christopher U. Missling, PhD, President and CEO of Anavex Life Sciences,
expressed gratitude for the collective efforts of those involved in the study.
He highlighted the company’s commitment to advancing blarcamesine as a
convenient oral treatment option for Alzheimer’s disease.
As the study progresses, the medical community remains optimistic about the potential of
Anavex’s innovative therapy to transform Alzheimer’s treatment and improve
patient outcomes significantly. Read this article for additional information.
More about Anavex on https://www.linkedin.com/company/anavex-life-sciences